Prostate Cancer

Prostate cancer is the second most common cancer in men worldwide, with approximately 1.4 million new cases diagnosed each year. The disease develops in the prostate gland, a walnut-sized organ below the bladder that produces fluid for semen. Cancer occurs when cells in the prostate acquire genetic mutations that cause uncontrolled growth. Most prostate cancers grow slowly and may never cause problems during a man's lifetime, but some are more aggressive and can spread to bones and other organs. A unique feature of prostate cancer is its dependence on male hormones (androgens), particularly testosterone, which fuel cancer cell growth—this hormonal sensitivity is exploited in treatment. Risk increases significantly with age, with most cases diagnosed after age 65. Family history matters—having a father or brother with prostate cancer roughly doubles risk, and inherited mutations in genes like BRCA1, BRCA2, and Lynch syndrome genes further increase susceptibility. Black men have higher incidence and mortality rates than other racial groups for reasons not fully understood but likely involving genetic, environmental, and healthcare access factors. Early-stage disease typically causes no symptoms, which is why screening with PSA (prostate-specific antigen) blood tests is common, though screening remains somewhat controversial since many detected cancers grow so slowly they'd never cause problems. Advanced disease can cause urinary symptoms, blood in urine or semen, erectile dysfunction, and bone pain if cancer has spread to the skeleton.

Treatment depends heavily on cancer aggressiveness and stage. For low-risk, slow-growing cancers, active surveillance (monitoring with regular PSA tests, exams, and biopsies without immediate treatment) is increasingly common, sparing men treatment side effects for cancers unlikely to threaten their lives. When treatment is needed for localized disease, surgery to remove the prostate (radical prostatectomy, increasingly performed robotically) or radiation therapy (external beam or brachytherapy using implanted radioactive seeds) are primary options with similar cure rates. For more aggressive or locally advanced disease, radiation is often combined with short-term hormone therapy. Hormone therapy (androgen deprivation therapy or ADT) that lowers testosterone through injections or pills forms the backbone of treatment for advanced disease. Over the past decade, next-generation hormone therapies—including abiraterone, enzalutamide, apalutamide, and darolutamide—have dramatically improved outcomes by more completely blocking testosterone's effects or production. These drugs extend survival by years when added to standard hormone therapy. For castration-resistant disease (cancer that progresses despite very low testosterone), additional options include chemotherapy (docetaxel, cabazitaxel), radium-223 for bone metastases, and PARP inhibitors (olaparib, rucaparib) for tumors with BRCA or other DNA repair gene mutations. Lutetium-177 PSMA radioligand therapy, recently approved, delivers targeted radiation to cancer cells expressing PSMA (prostate-specific membrane antigen), significantly benefiting men whose disease has progressed through other treatments. Many men with localized prostate cancer are cured, and even those with metastatic disease now often live for years with good quality of life.

Distinguishing aggressive cancers requiring immediate treatment from slow-growing ones that can be safely monitored remains imperfect—better methods to predict individual tumor behavior would prevent both overtreatment and undertreatment. Castration-resistant prostate cancer, while increasingly treatable, eventually progresses through available therapies, and additional options are needed for men whose disease has exhausted standard treatments. Treatment side effects significantly impact quality of life: surgery and radiation can cause erectile dysfunction and urinary incontinence, while hormone therapy produces hot flashes, fatigue, muscle loss, weight gain, cognitive changes, and increased risks of diabetes, cardiovascular disease, and osteoporosis—effects that accumulate over years of treatment. Managing these side effects while maintaining treatment effectiveness is an ongoing challenge. Bone metastases, which occur in the majority of men with advanced disease, cause pain, fractures, and complications requiring additional interventions. Oligometastatic disease—when cancer has spread to just a few sites—represents an intermediate stage where aggressive local treatment might extend survival, but optimal management strategies are still being defined. Immunotherapy has been less successful in prostate cancer than in many other cancers, and understanding why remains an active research question. Better biomarkers to predict treatment response before starting therapy would enable more personalized treatment selection and help avoid ineffective treatments.

Next-generation radioligand therapies targeting PSMA with different isotopes (including actinium-225) are in Phase 2 and Phase 3 trials, potentially offering more potent alternatives to lutetium-177 or options for resistant disease. Novel androgen receptor (AR) inhibitors and drugs targeting AR through different mechanisms are being tested to overcome resistance to current hormone therapies. Combination approaches pairing different classes of drugs—including dual hormone therapy, PARP inhibitors plus immunotherapy, and radioligand therapy combined with other treatments—are in advanced trials testing whether combinations work better than sequential single treatments. Immunotherapy strategies specifically designed for prostate cancer are being evaluated, including PROSTVAC and other cancer vaccines, checkpoint inhibitors combined with treatments that make tumors more visible to the immune system, and bispecific antibodies. For men with DNA repair gene mutations, trials are testing whether earlier use of PARP inhibitors or combinations of PARP inhibitors with other drugs improve outcomes. New bone-targeting agents beyond radium-223 are in development. Precision medicine approaches using genomic testing to match patients to targeted therapies are being refined through multiple trials. Researchers are evaluating whether treating oligometastatic disease aggressively with surgery or radiation (metastasis-directed therapy) extends survival compared to systemic treatment alone.

CAR-T cell therapy engineered to recognize PSMA or other prostate cancer markers is being developed, though challenges include helping these cells penetrate solid tumors and persist in the tumor environment. Bispecific antibodies that simultaneously bind prostate cancer cells and T cells are being created to force immune engagement. Scientists are identifying new therapeutic targets beyond the androgen receptor, including drugs targeting cancer cell metabolism, DNA damage response pathways, and survival signals that help cancer cells resist treatment. Next-generation imaging agents are being developed to detect small amounts of cancer earlier and more precisely than current scans, enabling better treatment targeting. Researchers are investigating the tumor microenvironment—the supportive cells, blood vessels, nerves, and immune cells surrounding cancer—to find ways to disrupt the ecosystem that protects cancer from treatment. Liquid biopsies analyzing tumor DNA in blood are being refined for earlier detection of recurrence, real-time treatment monitoring, and potentially screening high-risk men before cancer becomes detectable through standard methods. Artificial intelligence is being applied to predict treatment responses from genetic profiles, imaging patterns, and clinical data, and to discover new drug candidates. Scientists are exploring whether gut bacteria influence prostate cancer development and treatment response, with some evidence suggesting microbiome composition affects hormone therapy effectiveness. Researchers are developing drugs that target cancer stem cells and senescent cells that may contribute to treatment resistance and recurrence. Gene therapy approaches to correct cancer-causing mutations or deliver therapeutic genes are in early development. Novel drug delivery systems using nanoparticles aim to concentrate treatments at tumor sites while reducing side effects. Scientists are investigating combination approaches that attack cancer through multiple simultaneous mechanisms to prevent the development of treatment resistance.